Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma

The study showed a 75% objective response rate, 59% complete response rate, and 22.4 months median response duration. Credit: Gorodenkoff/Shutterstock.com.



  • Genentech FDA approval